CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome

• Main Authors: Cankun Zheng (Author), Wanling Xuan (Author), Zhenhuan Chen (Author), Rui Zhang (Author), Xiaoxia Huang (Author), Yingqi Zhu (Author), Siyuan Ma (Author), Kaitong Chen (Author), Lu Chen (Author), Mingyuan He (Author), Hairuo Lin (Author), Wangjun Liao (Author), Jianping Bin (Author), Yulin Liao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The prognosis of cardiorenal dysfunction induced by diabetes mellitus (DM), which belongs to cardiorenal syndrome type 5, is poor and its pathogenesis remains elusive. We have reported that CX3CL1 exacerbated heart failure and direct inhibition of CX3CL1 improved cardiac function. Emerging evidence...